# 治療計画書

療法名　キイトルーダ(3週毎)＋XELOX　療法　1サイクル 3 週

疾患名　治癒切除不能な進行・再発の胃癌

| 注射/内服/放射線 | Rp | 商品名 / 照射部位 | 用量(/回) / 用量(/日) / 照射量 | 投与ルート / 用法 | 投与時間 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注射 | 1 | 生理食塩液 | 50 ml | 点滴 | 15分 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 2 | キイトルーダ | 200 mg/body | 点滴 | 30分 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 生理食塩液 | 100 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 3 | 生理食塩液 | 50 ml | 点滴 | 15分 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 4 | グラニセトロン | 3 mg | 点滴 | 30分 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | デキサート | 6.6 mg | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 5 | エルプラット | 130 mg/㎡ | 点滴 | 2時間 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 5%糖液 | 250 ml | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 6 | 生理食塩液 | 50 ml | 点滴 | 15分 | ● | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 注射 | 8 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 1 | カペシタビン※ | 2000 mg/㎡ | 1日2回朝夕食後 | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | | | | | | | | | | | | | | |
| 内服 | 2 | デカドロン | 8 mg | 1日1(-2)回朝(昼)食後 | | | ● | ● | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 5 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 8 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 内服 | 10 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

特記事項

キイトルーダは最大35サイクルまで。
インラインフィルター(0.2～5μm)を使用すること。※カペシタビンは1日目の夕食後より服用開始。

| カペシタビン減量基準 | 1日投与量 | | |
|---|---|---|---|
| | 初回投与量 | 減量段階1 | 減量段階2 |
| 1.36㎡未満 | 2400mg/日 | 1800mg/日 | 1200mg/日 |
| 1.36㎡以上1.41㎡未満 | 3000mg/日 | | |
| 1.41㎡以上1.51㎡未満 | | 2400mg/日 | |
| 1.51㎡以上1.66㎡未満 | | | 1800mg/日 |
| 1.66㎡以上1.81㎡未満 | 3600mg/日 | | |
| 1.81㎡以上1.96㎡未満 | | 3000mg/日 | |
| 1.96㎡以上2.11㎡未満 | 4200mg/日 | | |
| 2.11㎡以上 | | | 2400mg/日 |

減量規定

| 薬品名 | エルプラット | カペシタビン | | | |
|---|---|---|---|---|---|
| 標準投与量 | 130 mg/㎡ | 上記参照 | | | |
| 1段階減量 | 100 mg/㎡ | | | | |
| 2段階減量 | 75 mg/㎡ | | | | |
| 3段階減量 | 50 mg/㎡ | 中止(CCr≦30) | | | |